TORONTO — August 5, 2021 — Levitee Labs Inc., a leading North American psychedelic medicine company, announced the appointment of Dr. Fady Hannah-Shmouni, MD FRCPC, as Chief Medical and Scientific Officer (CMSO) and President of Levitee Clinics and Pharmacies.
Dr. Hannah-Shmouni brings extensive experience in endocrinology, genomic medicine, and clinical research from his tenure as Principal Investigator at the National Institutes of Health (NICHD) and Associate Program Director of the NIH Endocrinology Fellowship Program.
In this role, Dr. Hannah-Shmouni will lead Levitee’s medical, scientific, and clinical operations strategy, overseeing the development of evidence-based therapeutic protocols for addiction treatment, mental health, and longevity medicine.
“Levitee Labs represents a remarkable opportunity to bring rigorous clinical science to an emerging field with profound therapeutic potential,” said Dr. Hannah-Shmouni. “I am committed to ensuring that our clinical programs are built on the strongest possible evidence base.”
Levitee Labs operates a growing network of clinics and pharmacies across Canada, focused on psychedelic-assisted therapy and integrative mental health care.
Source: Financial Post / GlobeNewswire, August 5, 2021
